IP Library › Granted Patent US 10,383,796
Granted Patent B2
US 10,383,796 · App. 15/676,433 · Granted Aug 20, 2019

Application and uses of PRG4 and therapeutic modulation thereof

Inventors: Edward R. Truitt (Medina, WA); Nicole Barbara Justis Truitt (Medina, WA)
Assignee: Lubris LLC
A61K8/02A61K8/64A61K8/735A61K9/0014A61K9/0048A61K9/0063A61K31/728A61K36/886A61K38/1709A61L27/50A61Q11/00A61Q19/00A61K9/0041A61K9/0056A61K9/0058C07K14/435C07K14/47C07K14/4725C07K2317/41
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,383,796
App. No.
15/676,433
Granted
Aug 20, 2019
Kind
B2
Abstract

The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Claims (18)

1. A method for filling or restoring tissue volume, skin turgor, texture and tightness in the face, neck or hand of a patient in need thereof comprising administering to the face, neck, or hand of the patient a composition comprising an effective amount of proteoglycan 4 (PRG4) having at least 95% primary amino acid sequence homology with the amino acid sequence of SEQ ID NO:1 in a dermatologically acceptable viscous solution.

2. The method of claim 1 , wherein the PRG4 comprises the amino acid sequence of SEQ ID NO:1.

3. The method of claim 1 , wherein the composition is administered to the face at one or more locations selected from the peri-orbital area, the lips, the malar area, the nasolabial folds, or the labio-mandibular folds.

4. The method of claim 1 , wherein the method further comprises administering a dermatologically effective amount of hyaluronic acid or collagen.

5. The method of claim 1 , wherein the method further comprises administering a dermatologically effective amount of carboxymethyl cellulose, polyethylene glycol, and/or polyethylene oxide.

6. The method of claim 1 , wherein the method further comprises administering a drug selected from antithrombogenic drugs, anti-inflammatory drugs, hormones, chemotactic factors, analgesics, growth factors, cytokines, osteogenic factors, anesthetics.

7. The method of claim 1 , wherein the method further comprises administering retinoic acid.

8. The method of claim 1 , wherein the method further comprises administering deuterium reduced water.

9. The method of claim 1 , wherein the composition is administered by injection into the dermis or hypodermis of the patient.

10. The method of claim 1 , wherein the PRG4 is recombinant PRG4.

11. The method of claim 1 , wherein the PRG4 is in a concentration of 10-10,000 μg/mL.

12. The method of claim 1 , wherein the PRG4 is human PRG4.

13. The method of claim 1 , wherein the PRG4 is an isolated or purified native PRG4.

14. A method for filling or restoring tissue volume, skin turgor, texture and tightness in a patient in need thereof, comprising injecting into the dermis or hypodermis of the patient in a selected area of the body a composition comprising an effective amount of proteoglycan 4 (PRG4) having at least 95% primary amino acid sequence homology with the amino acid sequence of SEQ ID NO:1 in a dermatologically acceptable viscous solution.

15. The method of claim 14 , wherein the PRG4 is in a concentration of 10-10,000 μg/mL.

16. The method of claim 14 , wherein the PRG4 is human PRG4.

17. The method of claim 14 , wherein the PRG4 is an isolated or purified native PRG4.

18. The method of claim 14 , wherein the PRG4 is recombinant PRG4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: TRUITT, EDWARD R.; TRUITT, NICOLE BARBARAJUSTIS
To: SINGULARIS, INC.
Reel/Frame 049610/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2019
From: SINGULARIS, INC.
To: LUBRIS LLC
Reel/Frame 049610/0205 →
Continuity (3)
Division 13321532
Provisional Application 61180525 · May 22, 2009
Related Publication 20180153776A1 · Jun 7, 2018
Cited By (4)
US 12,194,129 US 12,409,127 US 12,435,115 US 12,514,870